Skip to main content
. 2019 Nov 29;74(Suppl 5):v5–v16. doi: 10.1093/jac/dkz451

Table 5.

Cost-effectiveness analysis

Total costs (£) Incremental costs (£) Total QALYs Incremental QALYs mean ICER/QALY (£) NMB (£)
Standard of care 1234600679 590434
HepFriend in addition to standard of care 1238524344 3872848 590846 412 9408 4 360 457

NMB, net monetary benefit.